Tamiflu (Oseltamivir Phosphate), an antiviral drug sold by Roche under the brand name Tamiflu, is used for treating and preventing influenza virus strains A and B. It works by blocking a viral enzyme called neuraminidase that helps the flu virus to spread in the body. Tamiflu comes in capsule and powder for oral suspension forms. It is prescribed for influenza treatment in adults and children over 1 year of age. The drug offers a safe and effective protective action against influenza.
The Tamiflu (Oseltamivir Phosphate) Market is estimated to be valued at US$ 464.4 Mn in 2023 and is expected to exhibit a CAGR of 3.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
The growth of the Tamiflu (Oseltamivir Phosphate) Market is primarily driven by rising cases of influenza outbreaks worldwide. According to the World Health Organization (WHO), annual epidemics result in about 3 to 5 million cases of severe illness globally. The increasing threat of avian influenza strains and continual evolution of the influenza virus also necessitate adoption of antiviral drugs such as Tamiflu for influenza management. Moreover, growing awareness about influenza treatment and rising healthcare expenditure in developing nations are expected to support market expansion over the forecast period. However, development of alternative treatment options and expiration of Tamiflu’s U.S. patent are the major factors anticipated to hinder market growth. The patent expiration has enabled market entry of generic versions of oseltamivir phosphate in the U.S. such as Teva’s version approved by FDA in 2020.
Segment Analysis:
The Tamiflu market is dominated by the oral capsules segment, which accounts for over 80% of the total market share. This is because oral capsules offer convenience of consumption and flexibility in dosing compared to other formulations like suspensions. Oral capsules can be easily swallowed by people of all age groups including children and elderly. This drives its widespread adoption over other segments.
PEST Analysis:
Political: Healthcare reforms in various countries are pushing for higher access and lower costs of antiviral drugs like Tamiflu, which is benefiting its market growth.
Economic: Increase in per capita healthcare expenditure globally is increasing the affordability of branded drugs like Tamiflu for influenza treatment.
Social: Growing awareness about seasonal influenza and availability of effective treatment options is creating higher demand for drugs like Tamiflu.
Technological: Advancements in drug delivery technologies are helping manufacturers launch new formulations like orally disintegrating tablets for better patient compliance.
Key Takeaways:
The Global Tamiflu (Oseltamivir Phosphate) Market Size is expected to witness high growth, exhibiting CAGR of 3.1% over the forecast period, due to increasing prevalence of influenza infections globally.
The U.S. is the dominating as well as the fastest growing regional market for Tamiflu due to strong healthcare infrastructure and supportive government policies for influenza treatment and management.
Key players operating in the Tamiflu market are Roche, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Ltd., Mylan N.V., Apotex Inc., Sandoz AG, Accord Healthcare Ltd. Roche continues to be the global market leader due to its strong brand image and wide distribution network for Tamiflu.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it